LOS ANGELES--(BUSINESS WIRE)--
Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Arrowhead Pharmaceuticals, Inc. (“Arrowhead” or the “Company”) (Nasdaq: ARWR) concerning possible violations of federal securities laws.
To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or by email at [email protected].
The investigation focuses on the November 8, 2016 announcement where Arrowhead revealed that the U.S. Food & Drug Administration will be placing a clinical hold on its Heparc-2004 clinical study of ARC-520, likely due to deaths at the highest dose of an ongoing non-human primate toxicology study.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161111005690/en/
